Cogent Biosciences, Inc. (COGT)
32.01
+1.10
(+3.56%)
USD |
NASDAQ |
Oct 27, 16:00
32.02
0.00 (0.00%)
After-Hours: 20:00
Cogent Biosciences Enterprise Value : 5.011B for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 5.011B |
| October 26, 2026 | 4.822B |
| October 23, 2026 | 4.874B |
| October 22, 2026 | 4.891B |
| October 21, 2026 | 4.911B |
| October 20, 2026 | 4.879B |
| October 19, 2026 | 4.668B |
| October 16, 2026 | 4.584B |
| October 15, 2026 | 4.582B |
| October 14, 2026 | 4.348B |
| October 13, 2026 | 4.338B |
| October 12, 2026 | 4.628B |
| October 09, 2026 | 4.838B |
| October 08, 2026 | 4.680B |
| October 07, 2026 | 4.690B |
| October 06, 2026 | 4.731B |
| October 05, 2026 | 4.815B |
| October 02, 2026 | 4.841B |
| October 01, 2026 | 4.939B |
| September 30, 2026 | 5.013B |
| September 29, 2026 | 4.951B |
| September 28, 2026 | 4.985B |
| September 25, 2026 | 5.062B |
| September 24, 2026 | 4.911B |
| September 23, 2026 | 4.908B |
| Date | Value |
|---|---|
| September 22, 2026 | 5.117B |
| September 21, 2026 | 5.009B |
| September 18, 2026 | 4.923B |
| September 17, 2026 | 5.214B |
| September 16, 2026 | 5.102B |
| September 15, 2026 | 5.136B |
| September 14, 2026 | 5.251B |
| September 11, 2026 | 5.251B |
| September 10, 2026 | 5.366B |
| September 09, 2026 | 5.383B |
| September 08, 2026 | 5.572B |
| September 04, 2026 | 5.483B |
| September 03, 2026 | 5.516B |
| September 02, 2026 | 5.450B |
| September 01, 2026 | 5.469B |
| August 31, 2026 | 5.524B |
| August 28, 2026 | 5.468B |
| August 27, 2026 | 5.883B |
| August 26, 2026 | 5.819B |
| August 25, 2026 | 5.833B |
| August 24, 2026 | 5.735B |
| August 21, 2026 | 5.821B |
| August 20, 2026 | 5.577B |
| August 19, 2026 | 5.842B |
| August 18, 2026 | 5.936B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 79.13B |
| Arrowhead Pharmaceuticals, Inc. | 8.106B |
| Oncolytics Biotech, Inc. | 53.95M |
| Sangamo Therapeutics, Inc. | 40.67M |
| Sarepta Therapeutics, Inc. | 2.253B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -96.40M |
| Total Expenses (Quarterly) | 96.40M |
| EPS Diluted (Quarterly) | -0.5636 |
| Earnings Yield | -7.64% |
| Normalized Earnings Yield | -7.532 |